Now we know BTD was applied between 9/11 (10-K) an
Post# of 72436
Quote:
Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis;
My take of “other regulatory authorities” could be drug agencies in Europe, Asia, Australia, and South Africa since patents have been granted in those areas.
Quote:
The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa. All currently issued patents have an expiration date of 2032. Additional Brilacidin-OM patent applications are pending in other key markets including Russia and South Korea.
http://www.ipharminc.com/press-release/2017/1...-mucositis
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)